<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138618</url>
  </required_header>
  <id_info>
    <org_study_id>1.5 - 01 MARCH2010</org_study_id>
    <nct_id>NCT01138618</nct_id>
  </id_info>
  <brief_title>Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)</brief_title>
  <acronym>CHEMPAQ</acronym>
  <official_title>Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg Psychiatric Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clozapine remain the drug of choice for treatment resistant schizophrenia and up to 60% of
      patients not responding to other antipsychotics will respond to clozapine. However, the use
      of clozapine is restricted due to the risk of agranulocytosis and consequently the need for
      mandatory hematological monitoring. CHEMPAQ XBC is a point-of-care device that can be used in
      patients home and analyze WBC and granulocytes by a single capillary blood drop. This study
      aims to investigate whether this new procedure increases the acceptability of clozapine
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pain sensation</measure>
    <time_frame>Monthly for four months</time_frame>
    <description>Pain sensation was measured using a visual analog scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The benefits of CHEMPAQ</measure>
    <time_frame>Monthly for four months</time_frame>
    <description>Caregivers and patients were asked about the benefits of using CHEMPAQ for hematological clozapine monitoring.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">85</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>CHEMPAQ-venous-CHEMPAQ-venous</arm_group_label>
    <description>The two arms only differ in order of kind of blood samples.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venous-CHEMPAQ-Venous-CHEMPAQ</arm_group_label>
    <description>The two arms only differ in order of kind of blood samples.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Venous blod sample</intervention_name>
    <description>Regular venous blood sample withdrawn from the laboratory</description>
    <arm_group_label>CHEMPAQ-venous-CHEMPAQ-venous</arm_group_label>
    <arm_group_label>Venous-CHEMPAQ-Venous-CHEMPAQ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CHEMPAQ</intervention_name>
    <description>Capillary blood sample analyzed by CHEMPAQ</description>
    <arm_group_label>CHEMPAQ-venous-CHEMPAQ-venous</arm_group_label>
    <arm_group_label>Venous-CHEMPAQ-Venous-CHEMPAQ</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with clozapine
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treated with clozapine

          -  Compliant with blood monitoring

          -  Willing to give informed consent

        Exclusion Criteria:

          -  Prior case of agranulocytosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jimmi Nielsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg Psychiatric Hospital, Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg Psychiatric Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Center Aarhus</name>
      <address>
        <city>Aarhus</city>
        <zip>8240</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Center Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Centre Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Center Roskilde</name>
      <address>
        <city>Greve</city>
        <zip>2670</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Center Odense</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988 Sep;45(9):789-96.</citation>
    <PMID>3046553</PMID>
  </reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <last_update_submitted>November 4, 2011</last_update_submitted>
  <last_update_submitted_qc>November 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clozapine</keyword>
  <keyword>hematological monitoring</keyword>
  <keyword>CHEMPAQ</keyword>
  <keyword>Granulocytes</keyword>
  <keyword>WBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

